H.C. Wainwright analyst Raghuram Selvaraju downgraded Kezar Life Sciences to Neutral from Buy without a price target The company elected to announce the voluntary cessation of enrollment of new patients and dosing of ongoing patients in the Phase 2b PALIZADE trial of its lead candidate zetomipzomib, pending further evaluation, the analyst tells investors in a research note. The firm cites the current status of the PALIZADE program, and the uncertainty around the outlook for zetomipzomib, for the downgrade.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZR: